

# Robert M Bell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8233965/robert-m-bell-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12  
papers

423  
citations

6  
h-index

13  
g-index

13  
ext. papers

622  
ext. citations

6.8  
avg, IF

3.72  
L-index

#	Paper	IF	Citations
12	Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. <i>BMJ Open Respiratory Research</i> , <b>2021</b> , 8,	5.6	7
11	Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. <i>European Heart Journal</i> , <b>2021</b> , 42, 1866-1878	9.5	112
10	Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 764599	5.4	1
9	SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart. <i>JACC Basic To Translational Science</i> , <b>2019</b> , 4, 15-26	8.7	50
8	SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1454-1456	9.9	5
7	SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 435-437	18.1	30
6	Implications of Kidney Disease in the Cardiac Patient. <i>Interventional Cardiology Clinics</i> , <b>2014</b> , 3, 317-331	1.4	
5	Remote ischaemic conditioning and ischaemic heart disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2014</b> , 75 Suppl 1, C13-6	0.8	
4	Remote ischaemic conditioning and ischaemic heart disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2014</b> , 75, C13-6	0.8	
3	Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection. <i>Basic Research in Cardiology</i> , <b>2013</b> , 108, 331	11.8	19
2	Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 508-15	15.1	194
1	Post-COVID assessment in a specialist clinical service: a 12-month, single-centre analysis of symptoms and healthcare needs in 1325 individuals		3